A Focused, Late-Stage, First-in-Class Program.
A significant unmet need. A differentiated mechanism. A mechanism-aligned Phase 3 trial.
A defined path to a Phase 3 data readout
One late-stage molecule. A defined path to Phase 3 data. Celiac disease affects approximately 1% of the U.S. population, and no pharmacologic therapy is approved. Building on more than a decade of clinical development, larazotide acetate is advancing into a prevention-focused Phase 3 trial (CeD-LA-3002), with the first participant anticipated in the first quarter of 2027.
of the U.S. population has celiac disease
Many remain undiagnosed. Current management: a strict, lifelong gluten-free diet.
Report recurrent signs and symptoms despite a gluten-free diet
Gluten is pervasive in the food supply and subject to frequent cross-contact, so inadvertent exposure is common even among adherent patients.
First participant anticipated in CeD-LA-3002
A Phase 3 trial of approximately 414 participants, designed to evaluate protection against gluten-induced injury.
Request information
Investors interested in learning more about Interlude Biopharma’s investment opportunity, including the Phase 3 clinical trial (CeD-LA-3002), regulatory strategy, intellectual property, and financing structure, are encouraged to contact the company for additional information.
Confidential materials are available upon execution of a nondisclosure agreement (NDA).
Thank you.
Thank you for your interest in Interlude Biopharma. We’ll respond with next steps, including execution of a nondisclosure agreement, if applicable.
Advancing Larazotide Acetate Through Collaboration.
Interlude Biopharma welcomes discussions with organizations interested in advancing new treatments for celiac disease. Our lead investigational candidate, larazotide acetate, is a first-in-class oral tight junction regulator with FDA Fast Track designation. We are open to exploring strategic opportunities and collaborations, including licensing, commercialization partnerships, and potential corporate transactions.
- A differentiated mechanism: to our knowledge, the most advanced tight junction regulator in development for celiac disease, designed to act locally in the gut, upstream of immune activation
- A late-stage program with FDA Fast Track designation and a prevention-focused Phase 3 trial, with the first participant anticipated in 1Q 2027
- Long-term franchise potential, including d-larazotide, a next-generation peptide in preclinical development
Together, we can help advance a potential new option for people living with celiac disease.
Start a conversationForward-looking statements
This website contains forward-looking statements regarding Interlude Biopharma’s plans, the clinical development, anticipated trial timelines, regulatory milestones, and potential benefits of larazotide acetate. These statements reflect current expectations and are subject to risks and uncertainties, including those inherent in clinical development and regulatory review, that could cause actual results to differ materially from those anticipated. Interlude Biopharma undertakes no obligation to update these statements, except as required by applicable law.